Litcius/Paper detail

IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts

Sorel Kurbegovic, Karina Juhl, Kasper Sørensen, Julie Maja Leth, Gro Linno Willemoe, Anders Christensen, Yvonne Adams, Anja T. R. Jensen, Christian von Buchwald, Jane Skjøth‐Rasmussen, Michael Ploug, Knud J. Jensen, Andreas Kjær

2021Theranostics29 citationsDOIOpen Access PDF

Abstract

IRDye800CW-AE344 is a promising uPAR-targeted optical probe for FGS and a candidate for translation into human use.

Topics & Concepts

Urokinase receptorIn vivoMedicinePathologyGliomaCancer researchFluorescence-lifetime imaging microscopyU87StromaMolecular imagingReceptorFluorescenceImmunohistochemistryInternal medicineBiologyQuantum mechanicsBiotechnologyPhysicsNanoplatforms for cancer theranosticsGlioma Diagnosis and TreatmentCancer Research and Treatments
IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts | Litcius